Management of Rheumatoid Arthritis

1.  Is the risk of glucocorticoids (GCs) different if a specific cumulative dose has been used within a relatively short period of time, such as up to 3 or 6 months, or chronically over a number of years?

2.    Does the concomitant use of GCs at very low doses (1–3 mg prednisone equivalent) increase therapeutic success without producing unacceptable side effects?

3.    What are the effectiveness and safety profiles of (repeated) intramuscular glucocorticoids, for example, methylprednisolone 120 mg or triamcinolone 80 mg 1–4 times yearly?

4.    How safe and efficacious is the use of a JAKi after another JAKi has failed?

5.    Can we identify new biomarkers to stratify patients and to predict therapeutic responses or lack of response?

6.    How good is patient adherence to a bDMARD or tsDMARD and can non-adherence explain secondary loss of efficacy?

7.    Is Leflunomide equivalent to MTX as first line csDMARD therapy?

8.    Does the risk stratification for bDMARD/tsDMARD initiation based on presence of good or bad prognostic factors as recommended by EULAR translate into improved outcomes for both prognosis groups?

9.    What is the optimal treatment approach to refractory RA?

10.     What is the optimal (therapeutic) approach to arthralgia suspicious for progression to RA?